Avantor, Inc.

AVTR 10-Q · Q1 2026
API behind this page

AVTR Q1 2026 request

Playground key active
Request URL /api/financials?ticker=AVTR&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 1,581.4 1,581.4 0.0%
Show Product Lines breakouts
Proprietary 833.3 829.7 +0.4%
Third-party 748.1 751.7 -0.5%
Show Business Segments breakouts
Bioscience & Medtech Products 431.4 426.4 +1.2%
Bioscience & Medtech Products · Operating Segments 431.4 426.4 +1.2%
VWR Distribution & Services 1,150 1,155 -0.4%
VWR Distribution & Services · Operating Segments 1,150 1,155 -0.4%
Cost of Revenue 1,080.7 1,046.5 +3.3%
Gross Profit 500.7 534.9 -6.4%
Selling, General & Administrative 401.2 387.5 +3.5%
Operating Income 99.5 147.4 -32.5%
Interest Expense -42.9 -42.2 -1.7%
Gains Losses On Extinguishment Of Debt -0.6 — —
Show Debt Instrument breakouts
Euro term loans B-6 · EUR -0.6 — —
Other Non-Operating Income (Expense) -0.5 -19.5 +97.4%
Income Before Taxes 55.5 85.7 -35.2%
Income Tax Expense (Benefit) -12.2 -21.2 +42.5%
Net Income 43.3 64.5 -32.9%
EPS (Basic) 0.06 0.09 -33.3%
EPS (Diluted) 0.06 0.09 -33.3%
Wtd Avg Shares (Basic) 675.7 681.1 -0.8%
Wtd Avg Shares (Diluted) 676.8 682.4 -0.8%
Interest Expense -42.9 -42.2 -1.7%
Comprehensive Income 16.5 130.8 -87.4%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -26.8 66.3 -140.4%
Retained Earnings 43.3 64.5 -32.9%
Other Comprehensive Income -26.8 66.3 -140.4%
Interest Income Operating 10.5 7.9 +32.9%
Net Income Loss Available To Common Stockholders Basic 43.3 64.5 -32.9%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 279.3 315.7 -11.5%
Accounts Receivable 1,104.8 1,096.3 +0.8%
Inventory 810.3 750.1 +8.0%
Other Assets Current 209.9 120.3 +74.5%
Total Current Assets 2,404.3 2,282.4 +5.3%
Non-Current Assets
Property, Plant & Equipment 766.2 736.3 +4.1%
Goodwill 4,952.1 — —
Other Non-Current Assets 441.7 367.5 +20.2%
Total Assets 11,663 12,326.4 -5.4%
Intangible Assets 3,006.4 — —
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,661.3 — —
Other Intangible Assets 256.3 — —
Trade Names 88.8 — —
Other Assets
Other Intangible Assets Net 3,098.7 3,331.1 -7.0%
Current Liabilities
Current Portion of Long-Term Debt 37 — —
Accounts Payable 735.5 680.1 +8.1%
Employee Related Liabilities Current 161.7 140.6 +15.0%
Interest Payable Current 31.6 39.3 -19.6%
Other Liabilities Current 401.5 346.9 +15.7%
Total Current Liabilities 1,367.3 2,034.4 -32.8%
Non-Current Liabilities
Long-Term Debt 3,779.3 — —
Deferred Tax Liabilities 550.4 550 +0.1%
Other Non-Current Liabilities 377.3 364.6 +3.5%
Total Liabilities 6,074.3 6,228.2 -2.5%
Long-Term Debt 3,816.3 — —
Stockholders' Equity
Common Stocks Including Additional Paid In Capital 3,992 3,948.4 +1.1%
Treasury Stock Common Value -75.7 — —
Retained Earnings 1,716.1 2,267.5 -24.3%
Accumulated Other Comprehensive Income -43.7 -117.7 +62.9%
Total Stockholders' Equity 5,588.7 6,098.2 -8.4%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 13.2 13.7 -3.6%
Accumulated Other Comprehensive Income -43.7 -117.7 +62.9%
Accumulated Translation Adjustment -56.9 -131.5 +56.7%
Common Stock Including Additional Paid In Capital 3,992 3,948.4 +1.1%
Retained Earnings 1,716.1 2,267.5 -24.3%
Treasury Stock Common -75.7 — —
Total Liabilities & Equity 11,663 12,326.4 -5.4%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation And Amortization 105 99.7 +5.3%
Show Business Segments breakouts
Bioscience & Medtech Products 49.2 43.8 +12.3%
VWR Distribution & Services 55.8 55.9 -0.2%
Stock-Based Compensation 8.6 12.4 -30.6%
Show Award Type breakouts
Restricted Stock Units RSU 0.3 3.3 -90.9%
Provision For Accounts Receivable And Inventory 11.8 12 -1.7%
Deferred Income Taxes -10.2 -12.4 +17.7%
Amortization of Financing Costs 1.8 2.2 -18.2%
Foreign Currency Transaction Gain Loss Before Tax -1.4 1.9 -173.7%
Change in Accounts Receivable -40.8 -43.2 +5.6%
Change in Inventory -12.2 -17.6 +30.7%
Increase Decrease In Accounts Payable Trade 5.4 8.2 -34.1%
Increase Decrease In Interest Payable Net -15.7 -9.3 -68.8%
Increase Decrease In Other Operating Capital Net -37.1 -29.1 -27.5%
Other Non-Cash Items -0.4 1.9 -121.1%
Net Cash from Operations 58.7 109.3 -46.3%
Investing Activities
Capital Expenditures -33.5 -28 -19.6%
Other Investing Activities 0.8 -0.9 +188.9%
Net Cash from Investing -32.7 -28.9 -13.1%
Financing Activities
Repayments Of Long Term Debt -105.4 -31.3 -236.7%
Proceeds From Stock Options Exercised 1.9 2.6 -26.9%
Tax Withholding for Share Compensation -3.6 -4.9 +26.5%
Proceeds From Payments For Other Financing Activities -0.1 — —
Net Cash from Financing -107.2 -33.6 -219.0%
Debt Repayments (Q) — — —
Show Debt Instrument breakouts
Euro term loans B-6 · EUR 102.4 — —
Supplemental
Income Taxes Paid 10.4 16.7 -37.7%
Interest Paid 56.4 48.9 +15.3%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -4.9 7 -170.0%
Net Change in Cash -86.1 53.8 -260.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 282.2 318.5 -11.4%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key